NDAOPHTHALMICOINTMENT
Approved
Jan 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Aureomycin (chlortetracycline HCl) is a tetracycline antibiotic ointment approved in 1950 for ophthalmic use, primarily for bacterial eye infections and prevention of ophthalmia neonatorum. It functions by inhibiting bacterial protein synthesis through ribosomal binding. This product represents a legacy antibiotic with a well-established safety profile in neonatal and adult ocular care.
LOE Approaching
With LOE approaching and minimal current commercial activity, career growth on this product is limited; legacy products typically operate with small, maintenance-focused teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Aureomycin represents a legacy product with no current linked job openings and minimal career development trajectory. Roles on this product are primarily operational and compliance-focused, offering stability but limited growth, promotions, or exposure to innovation.
Brand Manager (legacy support)Sales Representative (hospital/retail)
Worked on AUREOMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.